SCOOP trial (screening for prevention of fractures in older women)
Participants: Women 70-85 years of age
Exclusion Criteria: On prescription anti-osteoporotic drugs
Intervention group: FRAX questionnaire for screening in all participants, with BMD measurement by dual energy x-ray absorptiometry in a selected subgroup based on higher risk
Screening based on FRAX 10-year hip fracture probability
Treatment was recommended in women identified to be at high risk of hip fracture
Proportion of individuals who had one or more osteoporosis-related fractures over a 5-year period
Proportions of participants who had at least one hip fracture
Any clinical fracture or mortality
Effect of screening on anxiety and health-related quality of life
12,483 eligible women were identified and participated in the trial
6,233 women were randomly assigned to screening
Treatment was recommended in 14%
Use of osteoporosis medication was higher at the end of year 1 in the screening group compared with controls (15% vs 4%), with uptake particularly high (78% at 6 months) in the screening high-risk subgroup
There was no difference in the primary outcome of incidence of all osteoporosis-related fractures
Hazard ratio [HR] 0.94, 95% CI 0.85–1.03; p=0·178
There was no difference in overall incidence of all clinical fractures
HR 0.94, 95% CI 0.86–1.03; p=0.183
There were no differences in mortality, anxiety levels, or quality of life
Screening did reduce the incidence of hip fractures
HR 0.72, 95% CI 0.59–0.89; p=0.002
Osteoporosis screening was feasible and reduced the incidence of hip fractures
111 individuals would need to be screened to avoid 1 hip fracture
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan